Maven Securities LTD Invests $594,000 in Rapport Therapeutics, Inc. $RAPP

Maven Securities LTD bought a new position in Rapport Therapeutics, Inc. (NASDAQ:RAPP) during the third quarter, Holdings Channel reports. The firm bought 20,000 shares of the company’s stock, valued at approximately $594,000.

Several other large investors have also added to or reduced their stakes in RAPP. Capital International Investors boosted its stake in Rapport Therapeutics by 30.7% during the 3rd quarter. Capital International Investors now owns 3,402,529 shares of the company’s stock valued at $101,055,000 after purchasing an additional 800,000 shares during the last quarter. Affinity Asset Advisors LLC purchased a new stake in shares of Rapport Therapeutics in the second quarter worth approximately $2,270,000. Baker BROS. Advisors LP lifted its holdings in shares of Rapport Therapeutics by 181.2% in the third quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company’s stock valued at $45,949,000 after purchasing an additional 997,000 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Rapport Therapeutics in the second quarter valued at approximately $130,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Rapport Therapeutics during the third quarter valued at approximately $143,000.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Wall Street Zen downgraded Rapport Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. The Goldman Sachs Group restated a “buy” rating on shares of Rapport Therapeutics in a research note on Friday, December 19th. Wells Fargo & Company lifted their price objective on shares of Rapport Therapeutics from $43.00 to $46.00 and gave the stock an “overweight” rating in a report on Wednesday, March 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapport Therapeutics in a research note on Thursday, January 22nd. Finally, TD Cowen reiterated a “buy” rating on shares of Rapport Therapeutics in a report on Monday, March 9th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $51.40.

Rapport Therapeutics Stock Up 0.4%

Rapport Therapeutics stock opened at $27.73 on Wednesday. The stock has a market cap of $1.33 billion, a P/E ratio of -9.70 and a beta of 1.50. The company’s 50 day moving average price is $28.11 and its two-hundred day moving average price is $27.30. Rapport Therapeutics, Inc. has a 52 week low of $7.73 and a 52 week high of $42.27.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings results on Tuesday, March 10th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.07). On average, equities analysts anticipate that Rapport Therapeutics, Inc. will post -3.65 EPS for the current year.

Insiders Place Their Bets

In other Rapport Therapeutics news, CEO Abraham Ceesay sold 5,833 shares of the company’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $26.12, for a total value of $152,357.96. Following the completion of the transaction, the chief executive officer owned 562,080 shares in the company, valued at $14,681,529.60. This represents a 1.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Krishnaswamy Yeleswaram sold 2,840 shares of the firm’s stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $30.05, for a total value of $85,342.00. Following the sale, the insider directly owned 296,991 shares of the company’s stock, valued at approximately $8,924,579.55. This represents a 0.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 50,253 shares of company stock worth $1,421,208 over the last 90 days. Company insiders own 13.57% of the company’s stock.

Rapport Therapeutics Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.